PROTAMINE DOES NOT AFFECT THE FORMATION OF CGMP OR CAMP IN PIG VASCULAR SMOOTH-MUSCLE CELLS IN RESPONSE TO VASODILATORS

被引:8
作者
CASTRESANA, MR [1 ]
ZHANG, LM [1 ]
NEWMAN, WH [1 ]
机构
[1] MERCER UNIV,SCH MED,MACON,GA 31207
关键词
ATRIAL NATRIURETIC PEPTIDE; CULTURED SMOOTH MUSCLE CELLS; ADENOSINE 3'5'-CYCLIC MONOPHOSPHATE; GUANOSINE 3'5'-CYCLIC MONOPHOSPHATE; SODIUM NITROPRUSSIDE; PROTAMINE; CRITICAL ILLNESS; NITRIC OXIDE; ISOPROTERENOL; FORSKOLIN;
D O I
10.1097/00003246-199505000-00024
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: Protamine has recently been shown to have a direct vasodilator action in isolated vascular tissue. As one possible mechanism for this action, it has been hypothesized that protamine might increase the response of vascular smooth muscle to the endothelium-derived relaxing factor, nitric oxide. In this study, we tested this hypothesis and examined the effect of protamine on other guanosine 3'5'-cyclic monophosphate (cGMP)- and adenosine 3'5'-cyclic monophosphate (cAMP)-dependent processes. Design: Prospective, repeated measures analysis of concentration-response curves. Setting: Anesthesia research laboratory in an academic medical center. Subjects: Cultured coronary artery smooth muscle cells from pig heart. Interventions: Sodium nitroprusside was used to mimic the action of the endothelium-derived relaxing factor by stimulating the soluble guanylyl cyclase and increasing intracellular cGMP. Atrial natriuretic peptide was used to stimulate the particulate guanylyl cyclase. Isoproterenol and forskolin were used to increase intracellular cAMP. The responses to these agents were determined in the presence and absence of protamine. Measurements and Main Results: In cultured vascular smooth muscle cells, sodium nitroprusside increased cGMP, the second messenger for endothelium-derived relaxing factor, in a concentration-dependent manner. In cells treated with protamine (32 to 250 mu g/mL), we could detect no effect of protamine on basal intracellular levels of cGMP until a concentration of 250 mu g/mL of protamine was used. At this concentration, protamine increased basal cGMP concentrations from 4.2 +/- 0.3 to 9.0 +/- 0.6 pmol/mg protein (p<.001), The response of intracellular cGMP to sodium nitroprusside in cells treated with 250 mu g/mL or other concentrations of protamine was not different from control. Likewise, we could detect no effect of protamine on intracellular cGMP stimulated with the atrial natriuretic peptide or on cAMP stimulated with the beta-adrenergic receptor agonist, isoproterenol, or with forskolin. Conclusions: These experiments show that protamine does not alter the responses of the intracellular second messengers, cGMP and cAMP, to the vasodilators sodium nitroprusside, atrial natriuretic peptide, isoproterenol, and forskolin. These results do not support the hypothesis that protamine sensitizes vascular smooth muscle cells to the endothelium-derived relaxing factor, nitric oxide.
引用
收藏
页码:939 / 943
页数:5
相关论文
共 18 条
[1]   EFFECTS OF PROTAMINE ON VASCULAR SMOOTH-MUSCLE OF RABBIT MESENTERIC-ARTERY [J].
AKATA, T ;
YOSHITAKE, J ;
NAKASHIMA, M ;
ITOH, T .
ANESTHESIOLOGY, 1991, 75 (05) :833-846
[2]   HEPARIN PREVENTS THE VASODILATING ACTIONS OF PROTAMINE ON HUMAN SMALL MESENTERIC-ARTERIES [J].
AKATA, T ;
KODAMA, K ;
YOSHITAKE, J ;
TAKAHASHI, S .
ANESTHESIA AND ANALGESIA, 1993, 76 (06) :1213-1221
[3]   ATRIOPEPTIN INHIBITION OF THROMBIN-MEDIATED CHANGES IN THE MORPHOLOGY AND PERMEABILITY OF ENDOTHELIAL MONOLAYERS [J].
BARON, DA ;
LOFTON, CE ;
NEWMAN, WH ;
CURRIE, MG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (09) :3394-3398
[4]   NITRIC-OXIDE GENERATION FROM NITROPRUSSIDE BY VASCULAR TISSUE - EVIDENCE THAT REDUCTION OF THE NITROPRUSSIDE ANION AND CYANIDE LOSS ARE REQUIRED [J].
BATES, JN ;
BAKER, MT ;
GUERRA, R ;
HARRISON, DG .
BIOCHEMICAL PHARMACOLOGY, 1991, 42 :S157-S165
[5]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[6]  
CERIONE RA, 1984, J BIOL CHEM, V259, P9979
[7]   ENDOTHELIUM-DERIVED RELAXING AND CONTRACTING FACTORS [J].
FURCHGOTT, RF ;
VANHOUTTE, PM .
FASEB JOURNAL, 1989, 3 (09) :2007-2018
[8]  
GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181
[9]  
HOBBHAHN J, 1988, ANESTH ANALG, V67, P253
[10]  
HORROW JC, 1985, ANESTH ANALG, V64, P348